SCHEMBL359456

SCHEMBL359456

Cn1cc(-n2ccc(=O)c(COc3ccc(N)cc3)n2)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 5/20 0.36
FGFR2 P21802 5/20 0.36
FGFR3 P22607 5/20 0.36
MAOB P27338 3/20 0.34
RAB9A P51151 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
MAOA P21397 1/20 0.34
PRMT5 O14744 2/20 0.34
NPC1 O15118 1/20 0.33
PKM P14618 1/20 0.33
APP P05067 1/20 0.33
PDE10A Q9Y233 1/20 0.32
MET P08581 1/20 0.32
AXL P30530 1/20 0.32
MERTK Q12866 1/20 0.32
MAP4K4 O95819 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14930551 0.90 ALDH1A1 (0.38) RAB9ASMN1; SMN2L3MBTL1NPC1PKM
SCHEMBL360085 0.87 PARP10 (0.43) MAOBMAP4K4
SCHEMBL10283805 0.87 NPC1 (0.32) FGFR1FGFR2FGFR3RAB9ASMN1; SMN2
SCHEMBL367903 0.85 MET (0.40) FGFR1FGFR2FGFR3PDE10AMET
SCHEMBL359308 0.85 HTT (0.40) MAOBRAB9ASMN1; SMN2MAPTNPC1
SCHEMBL12503425 0.83 MEN1 (0.40) RAB9ASMN1; SMN2L3MBTL1MAPTNPC1
SCHEMBL360971 0.83 TBXAS1 (0.41) FGFR1FGFR3RAB9ASMN1; SMN2MAPT
SCHEMBL14915754 0.83 PDE10A (0.38) FGFR1FGFR2FGFR3PDE10AMET
SCHEMBL360220 0.82 TBXAS1 (0.41) RAB9ASMN1; SMN2L3MBTL1NPC1TSHR
SCHEMBL360624 0.81 IRAK4 (0.37) FGFR1FGFR2FGFR3RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US claimed
EP-2593107-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-05-22 EP disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116231-A1 TYROSINE KINASE INHIBITORS ABL1, ERBB2, MET FGFR1 58/4885FGFR2 205/4885FGFR3 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.